癌症疼痛市場規模、佔有率和成長分析（按藥物類別、適應症、配銷通路、給藥途徑、最終用戶和地區）- 2025-2032 年行業預測

2023 年全球癌症疼痛市場規模價值 75 億美元，預計將從 2024 年的 79.2 億美元成長到 2032 年的 122.5 億美元，預測期內（2025-2032 年）的複合年成長率為 5.6%。

全球癌症疼痛市場正在經歷顯著成長，這歸因於癌症發病率增加、人口老化、醫療支出增加以及醫療保健公司研發舉措加大等幾個關鍵因素。根據國際癌症研究機構的數據，2020 年美國診斷出的新癌症病例約 180 萬例，癌症相關死亡病例約 606,520 例。老化社會特別容易受到各種癌症的侵害，據報道，乳癌的診斷平均年齡為 61 歲，結直腸癌的診斷平均年齡為 68 歲，肺癌的診斷平均年齡為 70 歲，前列腺癌的診斷平均年齡為 66 歲。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管分析
• 技術分析

癌症疼痛市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概況
• 鴉片類藥物
• 羥可酮
• 氫可酮
• NSAIDs
• Ibuprofen
• 萘普生
• 其他

癌症疼痛市場規模（按適應症和複合年成長率） (2025-2032)

• 市場概況
• 肺癌
• 大腸直腸癌
• 乳癌
• 攝護腺癌
• 血癌
• 其他

癌症疼痛市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 網路藥局
• 零售藥局

癌症疼痛市場規模（按給藥途徑和複合年成長率） (2025-2032)

• 市場概況
• 口服
• 腸外
• 其他

癌症疼痛市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院
• 居家照護
• 專科門診
• 其他

癌症疼痛市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Pfizer（USA）
• Johnson & Johnson（USA）
• Purdue Pharma（USA）
• Novartis（Switzerland）
• Heron Therapeutics（USA）
• Teva Pharmaceutical Industries（Israel）
• Eli Lilly and Company（USA）
• AstraZeneca（UK）
• GlaxoSmithKline（UK）
• Merck & Co., Inc.（USA）

結論和建議

Global Cancer Pain Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 7.92 billion in 2024 to USD 12.25 billion by 2032, growing at a CAGR of 5.6% during the forecast period (2025-2032).

The global cancer pain market is experiencing significant growth, driven by several key factors: the increasing prevalence of cancer, an aging demographic, rising healthcare expenditures, and heightened research and development initiatives by healthcare companies. In 2020, the American Cancer Society noted approximately 1.8 million new cancer diagnoses and about 606,520 cancer-related fatalities in the U.S. Moreover, colorectal cancer was responsible for around 1,065,960 new cases globally, according to the International Agency for Research on Cancer. The aging population is particularly vulnerable to various cancers, with median diagnosis ages reported as 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer, and 66 for prostate cancer, as highlighted by the National Cancer Institute.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Pain Market Segments Analysis

Global Cancer Pain Market is segmented by Drug Class, Indication, Distribution Channel, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Opioids, Oxycodone, Hydrocodone, NSAIDs, Ibuprofen, Naproxen and Others. Based on Indication, the market is segmented into Lung cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Pain Market

The Global Cancer Pain market is significantly driven by technological advancements in pain management strategies, innovative drug delivery systems, and the development of personalized treatment options. These innovations not only improve the effectiveness of pain relief methods but also make them more accessible to patients suffering from cancer-related pain. As research and development continue to evolve, the emergence of new technologies is expected to optimize patient outcomes, streamline treatment protocols, and ensure that individuals have better access to the most suitable pain management solutions for their unique needs. This dynamic landscape continues to shape the market and enhance the quality of life for those affected.

Restraints in the Global Cancer Pain Market

The growth of the global cancer pain market may be hampered by the risks of drug tolerance and dependence that can arise from the use of pain medications, along with the possibility of experiencing a range of side effects. These factors contribute to concerns among healthcare providers and patients alike, potentially influencing their willingness to utilize certain pharmacological interventions. Additionally, the fear of adverse reactions may prompt individuals to seek alternative pain management strategies, further restricting the market's expansion. Consequently, addressing these challenges is essential for promoting a more favorable environment for growth within this crucial sector.

Market Trends of the Global Cancer Pain Market

The Global Cancer Pain market is witnessing a significant trend towards personalized pain management, driven by an increasing emphasis on individualized treatment strategies that leverage genetic and molecular profiling. This shift reflects a broader movement in healthcare to tailor therapies to the unique characteristics of patients, enhancing the efficacy and outcome of pain management in cancer care. By integrating advanced diagnostics and biomarker analysis, stakeholders in the market are innovating targeted pain relief solutions designed to optimize patient comfort and overall quality of life. This trend is expected to accelerate growth in the market, fostering advancements in treatment protocols and patient adherence.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Analysis
• Technology Analysis

Global Cancer Pain Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Opioids
• Oxycodone
• Hydrocodone
• NSAIDs
• Ibuprofen
• Naproxen
• Others

Global Cancer Pain Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Lung cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

Global Cancer Pain Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Cancer Pain Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Cancer Pain Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Cancer Pain Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations